Blood Screening Market - Trends Forecast Till 2028

Blood Screening Market By Type (Reagents & Kits, Instruments, Software & Services), Technology (Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Next-Generation Sequencing (NGS), Nucleic Acid Test, Western Blot Assay, Others), Disease Type (Oncology, Diabetes Mellitus, Cold & Flu, Cholesterol, Infectious Diseases, Respiratory Diseases, Hiv/Aids, Others), Application (Diagnostic Centers, Blood Bank, Hospitals, Clinics, Ambulatory Surgical Centers), Geography (North America, Europe, Asia-Pacific, Middle East and Africa and South America)

Published Date: September, 2020

Base Year Estimate: 2019

Report ID: D-HC-BSM-28

Format:  

Number of Pages: 227

Domain: Healthcare

Blood Screening Market – Trends Forecast Till 2028

The global blood screening market is anticipated to reach USD 3.21 billion by 2020 growing at a CAGR of 9.2% during the forecasting period, 2020-2028. Blood screening is a screening process used in the healthcare vertical for providing a safe blood supply and also helps in minimizing the problems associated with transfusion-transmitted infection. Factors such as the rise in demand for donated blood and the rising number of blood donations and blood donors are some of the major drivers for the market of blood screening

Blood Screening Market – Trends Forecast Till 2028

The global blood screening market is segmented into type, technology, disease type, application, and geography.

The type segment is segmented into reagents & kits, instruments, and software & services. Reagent & Kits has been segmented into ELISA reagents & kits, nat reagents & kits. Elisa reagents & kits have been further segmented into immunosorbents, conjugates, substrates, controls, sample diluents, and wash solutions. NAT reagents & kits have been further segmented into probes and primers, enzymes and polymerases, labeling and detection reagents, standards and controls, buffers, nucleotides, and solutions.

On the basis of type, the NAT reagents & kits segment accounted for the market share for the blood screening market in the forecast period 2020-2028.

The technology segment is segmented into Enzyme-Linked Immunosorbent Assay (ELISA), Rapid Tests, Next-Generation Sequencing (NGS), Nucleic Acid Test, Western Blot Assay, Others. Enzyme-Linked Immunosorbent Assay (ELISA) on the basis of type has been further segmented into Colorimetric Immunoassay (CI), Chemiluminescence Immunoassay (CLIA), and Fluorescence Immunoassay (FIA). Enzyme-Linked Immunosorbent Assay (ELISA) on the basis of generation has been segmented into first-generation ELISA, second-generation ELISA, third-generation ELISA, fourth-generation ELISA. The nucleic Acid test has been further segmented into Real-Time Polymerase Chain Reaction (PCR) and Transcription-Mediated Amplification (TMA).

The disease Type segment is segmented into Oncology, Diabetes Mellitus, Cold & Flu, Cholesterol, Infectious Diseases, Respiratory Diseases, Hiv/Aids and Others

Application segment is segmented into Diagnostic Centers, Blood Bank, Hospitals, Clinics, and Ambulatory Surgical Centers

Geographically, the global blood screening market is sub-segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America, and insights are provided for each region and major countries within the regions.

North America region is the largest contributor to the global blood screening market in the forecast period 2020-2028.

Key players in global blood screening market F. Hoffmann-LA Roche Ltd, Abbott, Thermo Fisher Scientific Inc., Siemens AG, Bio-Rad Laboratories, Inc., BD, Beckman Coulter, Inc., Biomérieux SA, Cepheid (A Subsidiary Of Danaher Corporation), Enzo Biochem Inc., Grifols International, S.A., Hologic Inc., Immucor, Inc., Meridian Bioscience, Inc., Ortho Clinical Diagnostics among others

The companies have come up with various promotional activities in from of launch, investment, acquisition, and other, for instance:

  • In 2016, Siemens Healthineers has acquired Conworx Technology GmbH based out in Germany for point-of-care device interfaces and data management solutions. 
  • In 2018, Thermo Fisher Scientific has announced the launch of Oncomine TCR Beta-SR Assay, a next-generation sequencing (NGS) solution which can be used for the immuno-oncology research field

Available Customizations

In addition to the market data for the blood screening market, Delvens. offers client-centric reports and customized according to the company’s specific demand and requirement.

Research Methodology

Secondary Research

This research method involved the usage of extensive secondary sources (such as directories and databases)—Hoovers, Avention, annual reports, investor presentation, a conference like Jefferies conference)—to identify and collect information useful for this study of the blood screening market. The purpose of secondary research is to identify and collection of extensive, technical, market-oriented, and commercial studies of the global blood screening market. Through secondary research, the market is classified and segmented as per industry trends, developments, regional markets, products, and technological developments. 

Primary Research

The primary sources mainly included several industry experts from the core and related industries and suppliers, manufacturers, distributors, alliances, and organizations related to all segments of this industry’s supply chain. In-depth interviews were conducted with various primary respondents—including key industry participants, subject matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts—to obtain and verify critical qualitative and quantitative information as well as to assess future prospects. The following figure depicts the market research methodology used in drafting this report on the blood screening market.

Primary Respondent breakdown is provided below:

Blood Screening Market – Trends Forecast Till 2028

Market Sizing

Top-down and bottom approaches were used to derive the market estimate and validate the total revenue of the blood screening market. This approach has also been used to derive the market for segmentation and sub-segmentation. 

Data Validation

Impact analysis has been conducted for deriving the market size. After collecting the in-depth quantitative and qualitative data, we contact the primary respondents in order to gain a 98.8% of confidence level on our data.

The data validation involves the primary research from the industry experts belonging to:

  • Leading Companies
  • Suppliers & Distributors
  • Manufacturers
  • Consumers
  • Industry/Strategic Consultants 

Reasons to Acquire

  • Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors
  • Gain authentic and granular data access for the blood screening market so as to understand the trends and the factors involved in changing market situations
  • Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
  • In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Report Scope

 

Report Features

Description

Market Revenue In 2020

USD 3.21 billion

Growth Rate

CAGR of 9.2% during the forecasting period, 2020-2028

Historical Data

2017-2018

Forecast Years

2020-2028

Base Year 

2019

Units Considered

Revenue in USD billion and CAGR from 2020 to 2028

Report Segmentation

Type, Technology, Disease Type, Application, and Geography

Report Attribute

Market Revenue Sizing (Global, Regional and Country Level) Company Share Analysis, Market Dynamics, Company Profiling

Regional Level Scope

North America, Europe, Asia-Pacific, South America, and the Middle East and Africa

Country Level Scope

U.S., Japan, Germany, U.K., China, India, Brazil, UAE, South Africa (50+ Countries Across the Globe)

Companies Profiled

F. Hoffmann-LA Roche Ltd, Abbott, Thermo Fisher Scientific Inc., Siemens AG, Bio-Rad Laboratories, Inc., BD, Beckman Coulter, Inc., Biomérieux SA, Cepheid (A Subsidiary Of Danaher Corporation), Enzo Biochem Inc., Grifols International, S.A., Hologic Inc., Immucor, Inc., Meridian Bioscience, Inc., Ortho Clinical Diagnostics among others

Available Customization 

In addition to the market data for the blood screening market, Delvens. offers client-centric reports and customized according to the company’s specific demand and requirement.

 

Please complete the form below:

This website is secure and your personal details are safe. Privacy Policy

Please complete the form below:

This website is secure and your personal details are safe. Privacy Policy

Please complete the form below:

This website is secure and your personal details are safe. Privacy Policy

Choose License Type
Global: 50+ Countries

Note: Report data and information will be by Country.


Regional Report

Note: Report data and information will be by Country.


Country Specific Report

Bundle Reports

50% Discount on all additional reports  

Special Pricing

Avail customised purchase options to meet your specific research requirements.

Custom Tailored Services

Delvens. offers transformed research reports where syndicated reports are not sufficient to provide solutions to your business.

Subscription Model

Get latest and trending updates throughout the year on the reports you buy.